CTKB Stock Overview
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Cytek Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.66 |
| 52 Week High | US$12.31 |
| 52 Week Low | US$3.80 |
| Beta | 1.37 |
| 1 Month Change | -11.42% |
| 3 Month Change | -31.14% |
| 1 Year Change | -47.83% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.83% |
Recent News & Updates
Shareholder Returns
| CTKB | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -4.4% | 4.1% | 1.2% |
| 1Y | -47.8% | 4.7% | 24.9% |
Price Volatility
| CTKB volatility | |
|---|---|
| CTKB Average Weekly Movement | 10.3% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 676 | Wenbin Jiang | cytekbio.com |
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils.
Cytek Biosciences, Inc. Fundamentals Summary
| CTKB fundamental statistics | |
|---|---|
| Market cap | US$760.09m |
| Earnings (TTM) | -US$12.15m |
| Revenue (TTM) | US$193.02m |
3.8x
P/S Ratio-61.0x
P/E RatioIs CTKB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTKB income statement (TTM) | |
|---|---|
| Revenue | US$193.02m |
| Cost of Revenue | US$83.59m |
| Gross Profit | US$109.43m |
| Other Expenses | US$121.57m |
| Earnings | -US$12.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.093 |
| Gross Margin | 56.69% |
| Net Profit Margin | -6.29% |
| Debt/Equity Ratio | 0.6% |
How did CTKB perform over the long term?
See historical performance and comparison